This review analyzes the clinical potential of the stromal vascular fraction (SVF), a heterogeneous cell population derived from adipose tissue with therapeutic promise in regenerative medicine. SVF consists of cells such as pericytes, smooth muscle cells, and adipose-derived stem cells (ADSCs), which contribute to tissue regeneration and repair through differentiation and secretion of growth factors. The review systematically analyzed 473 articles, with 16 meeting inclusion criteria, to evaluate SVF's composition, mechanisms of action, clinical applications, and future directions. SVF has shown efficacy in various clinical settings, including orthopedics, cardiology, plastic and reconstructive surgery, and wound healing. It has demonstrated improvements in pain, tissue regeneration, graft survival, and wound healing, along with immunomodulatory and anti-inflammatory properties. However, challenges remain, including standardization of protocols, optimal dosage and delivery methods, and long-term follow-up studies. The review highlights the need for further research to address these limitations and fully realize SVF's therapeutic potential. Future studies should focus on clarifying cellular dynamics, conducting long-term clinical trials, and investigating the dose-response relationship. The review also discusses the importance of regulatory guidelines and ethical considerations in the clinical application of SVF. Overall, SVF represents a promising tool in regenerative medicine with potential applications across multiple medical disciplines.This review analyzes the clinical potential of the stromal vascular fraction (SVF), a heterogeneous cell population derived from adipose tissue with therapeutic promise in regenerative medicine. SVF consists of cells such as pericytes, smooth muscle cells, and adipose-derived stem cells (ADSCs), which contribute to tissue regeneration and repair through differentiation and secretion of growth factors. The review systematically analyzed 473 articles, with 16 meeting inclusion criteria, to evaluate SVF's composition, mechanisms of action, clinical applications, and future directions. SVF has shown efficacy in various clinical settings, including orthopedics, cardiology, plastic and reconstructive surgery, and wound healing. It has demonstrated improvements in pain, tissue regeneration, graft survival, and wound healing, along with immunomodulatory and anti-inflammatory properties. However, challenges remain, including standardization of protocols, optimal dosage and delivery methods, and long-term follow-up studies. The review highlights the need for further research to address these limitations and fully realize SVF's therapeutic potential. Future studies should focus on clarifying cellular dynamics, conducting long-term clinical trials, and investigating the dose-response relationship. The review also discusses the importance of regulatory guidelines and ethical considerations in the clinical application of SVF. Overall, SVF represents a promising tool in regenerative medicine with potential applications across multiple medical disciplines.